Clinical trials

Condition   Drug Name  
Study NEOSH-101 in androgenic alopecia: The NCT00471510 study
Design Randomized; Double-blind; Multicenter
Patients 140
Treatment Regimen NEOSH-101 0.5% top. o.d. x 16 wks (n=35); NEOSH-101 1% top. o.d. x 16 wks (n=35); NEOSH-101 2% top. o.d. x 16 wks (n=35); Placebo (n=35)
Conclusions A phase ll study initiated in May 2007 will evaluate the safety and efficacy of NEOSH-101 in patients with androgenetic alopecia
Reference(s) Dose-ranging efficacy study of topical NEOSH101 to treat male pattern hair loss (NCT00471510)
ClinicalTrials.gov Web Site 2007